PHASE 2 STUDY OF IRINOTECAN AS THE THIRD LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NJLCG0703)

被引：0
|
作者：
Watanabe, K. [1 ]
Maemondo, M. [1 ]
Inoue, A. [2 ]
Ishimoto, O. [3 ]
Morikawa, N. [4 ]
Matsubara, N. [1 ]
Sakakibara, T. [2 ]
Fukuhara, T. [2 ]
Sugawara, S. [3 ]
Nukiwa, T. [2 ]
机构：
[1] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi 9811293, Japan
[2] Tohoku Univ, Sendai, Miyagi 980, Japan
[3] Sendai Kousei Hosp, Sendai, Miyagi, Japan
[4] Saka Hosp, Shiogama, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：156 / 156
页数：1
相关论文
共 50 条
  • [41] Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
    A Horiike
    K Kudo
    E Miyauchi
    F Ohyanagi
    K Kasahara
    T Horai
    M Nishio
    [J]. British Journal of Cancer, 2011, 105 : 1131 - 1136
  • [42] Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
    Horiike, A.
    Kudo, K.
    Miyauchi, E.
    Ohyanagi, F.
    Kasahara, K.
    Horai, T.
    Nishio, M.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 105 (08) : 1131 - 1136
  • [43] Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer
    Kakolyris, S
    Kouroussis, C
    Souglakos, J
    Agelaki, S
    Kalbakis, K
    Vardakis, N
    Vamvakas, L
    Georgoulias, V
    [J]. LUNG CANCER, 2001, 34 : S71 - S76
  • [44] A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: Final report
    Pillot, Giancarlo A.
    Read, William L.
    Hennenfent, Kristin L.
    Marsh, Sharon
    Viswanathan, Avinash
    Cummings, Kristopher
    McLeod, Howard L.
    Govindan, Ramaswamy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (09) : 972 - 978
  • [45] XPD polymorphism in second-line treatment with gemcitabine or irinotecan in advanced non-small cell lung cancer (NCSLC) patients
    Camps, C
    Alonso, G
    de Las Peñas, R
    Provencio, M
    Terrasa, J
    Lopez-Vivanco, G
    Artal, A
    Garcia-Gomez, R
    Pujol, E
    Rosell, R
    [J]. LUNG CANCER, 2005, 49 : S118 - S118
  • [46] Phase II study with weekly irinotecan and cisplatin as a 2nd-line chemotherapy for non-small cell lung cancer (NSCLC)
    Takiguchi, Yuichi
    Asaka-Amano, Yoshiko
    Moriya, Tetsuro
    Kawashima, Tatsuo
    Mizoo, Akira
    Kurosu, Katsushi
    Nagao, Keiichi
    Kuriyama, Takayuki
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 237 - 237
  • [47] Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer
    de Marinisa, Filippo
    Grossi, Francesco
    [J]. ONCOLOGIST, 2008, 13 : 14 - 20
  • [48] Biological predictors of third-line treatment outcomes in patients with advanced non-small cell lung cancer.
    Vassias, Antonios
    Vassos, Dimitrios
    Grapsa, Dimitra
    Bakakos, Petros
    Rovina, Nikoletta
    Syrigos, Konstantinos N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Second-line treatment options in advanced non-small cell lung cancer
    de Marinis, Filippo
    Ricciardi, Serena
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S258 - S271
  • [50] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    [J]. DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
12345